Sara Nunnery, MD, MSCI, and Kelly E. McCann, MD, PhD, discuss practice-changing data with T-DXd for HER2-positive breast cancer.
Related to this article
T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
European Commission Approves Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ mTNBC
2
Teclistamab-Based Induction Elicits High MRD Negativity Rates in Transplant-Eligible Newly Diagnosed Myeloma
3
Bomedemstat Yields Spleen Reduction, Symptom Improvement in Advanced Myelofibrosis
4
Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer
5